Published customer image:
Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the evaluation of MHC class II expression on dendritic cells by flow cytometry.
Image caption:
Time course of DC differentiation from H1 hESC. Cells were harvested from cultures at various time points and analysed by flow cytometry for the onset of hematopoiesis and the appearance of DC. (a) Cells harvested at day 20 of culture showing expressing of CD45 but lack of myeloid commitment, as evidenced by staining for CD13, CD14, and CD11c. Open histograms show levels of background staining using isotype-matched control antibodies. (b) Appearance of CD45int cells at day 27 of culture, accompanied by the upregulation of myeloid-specific markers. (c) Photomicrograph, taken at day 28 of culture, showing the morphology of DC, including veils of cytoplasm and long dendrites (inset) (×40 magnification). (d) Cells harvested at day 33 of culture, showing the appearance of a CD45hi population containing predominantly DC progenitors expressing CD14, CD11c, CD86 and MHC class I. (e) Phenotype of immature and mature H1-DCs compared with human moDC. DCs were cultured either in medium alone or medium supplemented with the maturation cocktail and stained for MHC class II, the maturation marker CD83 and classical costimulatory molecules. Dead cells were excluded from the analysis using 7-AAD. Dashed histograms show the phenotype of immature DCs while the filled histograms represent mature DCs. Open histograms depict background staining using isotype-matched controls.

From: Kathryn M. Silk, Alison J. Leishman, Kevin P. Nishimoto, Anita Reddy, and Paul J. Fairchild, “Rapamycin Conditioning of Dendritic Cells Differentiated from Human ES Cells Promotes a Tolerogenic Phenotype,”
Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 172420, 11 pages, 2012.

Published customer image:
Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the treatment on monocytes in vitrodetection of MHC class II on
Image caption:
Ligand engagement of HLA class II molecules up regulates MyD88, IL-1R1, and TNF-a in CD14+ human monocytes treated with SEB, SEA, or mAb directed against MHC-class II molecules. (A) Transcriptional activation of MyD88, IL-1R1AcP and TNF-a in HLA-DR positive primary monocytes treated with 200 ng SEB/ml (optimum dose), mAbs (10 µg/ml, optimum dose) directed against MHC-class II molecule (anti-DR-DP-DQ or LB3.1) or unrelated control antibody OKT3 was examined by semi-quantitative RT-PCR. Data shown is one of 3 similar experiments; (B) Agonists binding to TLR4 or HLA class II molecules on CD14+ monocytes induced transcriptional up regulation of MyD88. Real time RT-PCR was used to determine relative expression of MyD88 normalized to the expression of ß-actin. Expression levels are determined as means +/- SD. Data presented as one of 3 similar experiments. Significance compared to untreated control (*) was assigned as P=0.0001. (C) MHC class II molecule dependence of SEB- induced TNF- a gene expression. Pretreatment of monocytes in ice with anti-DR-DP-DQ at optimum dose (10 µg/ml) followed by SEB stimulation resulted in reduced TNF- a gene expression. Transcriptional activation of TNF- a expression normalized to the expression of ß-actin. Expression levels of TNF- a are expressed as means +/- SD. Significance was assigned (*) or (**) as P values =0.003 comparing untreated vs treatment groups with anti-DR-DP-DQ, SEB or SEB vs anti-DR-DP-DQ+SEB respectively. (D) Confocal images show expression of HLA-DR (green) and intracellular MyD88 (red) proteins in CD14+ monocytes treated with HLA class II- ligands or control antibody OKT3 for 16 h; Scale bar = 5 µm; (E) intracellular expression of MyD88 protein in activated monocytes. Primary monocytes (CD14+, CD3-) were activated as described earlier, permeabilized and labeled with primary MyD88 antibody followed by PE-labeled secondary antibody and analyzed by flow cytometry. Histogram represents a MHC class II ligand-induced increase in expression of MyD88 protein compared to non-MHC class II ligand (OKT3).

From: Kissner TL, Ruthel G, Alam S, Ulrich RG, Fernandez S, et al. (2011) Activation of MyD88 Signaling upon Staphylococcal Enterotoxin Binding to MHC Class II Molecules.
PLoS ONE 6(1): e15985.

Published customer image:
Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the evaluation of HLA DR expression on dendritic cells by flow cytometry.
Image caption:
Upregulation of DC class II expression by paclitaxel is not mediated via TLR-4. DC were cultured for 2 h with LPS or paclitaxel in the presence or absence of anti-TLR-4 Abs prior to washing and reculture for a further 24 h. Anti-TLR4 antibody did reduce class II expression after exposure to LPS, but not to paclitaxel at high dose. Numbers in parenthesis represent MFI of class II detection. Data is representative of 3 independent experiments from 3 donors.

From: John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, Pandha H. Differential effects of Paclitaxel on dendritic cell function.
BMC Immunol. 2010 Mar 19;11:14.

Published customer image:
Mouse anti Human HLA DP DQ DR antibody, clone WR18 used for the treatment of human mononuclear cells in vitro
.Image caption:
Inhibition of proliferation by anti-MHC class II antibody. Mononuclear cells from cord blood (?) or adult PBMC (¦) were preincubated with MAb MCA477, and assays of proliferation to different antigens were carried out. Inhibition was expressed as the SI for treated cells compared to that for untreated cells, which was normalized to 100%. Each bar represents the mean and standard deviation from three assays.

From: Chia JS, You CM, Hu CY, Chiang BL, Chen JY. Human T-cell responses to the glucosyltransferases of Streptococcus mutans. Clin Diagn Lab Immunol. 2001 Mar;8(2):441-5.

Figure A. RPE conjugated Mouse anti Human CD11c (MCA2087PE) and FITC conjugated Mouse IgG2a isotype control (MCA929F). Figure B. RPE conjugated Mouse anti Human CD11c (MCA2087PE) and FITC conjugated Mouse anti Human HLA DP/DQ/DR (MCA477F). All experiments performed on human Peripheral blood mononuclear cells in the presence of human SeroBlock (BUF070A).

Figure A. FITC conjugated Mouse anti Human CD86 (MCA1118F) and RPE conjugated Mouse IgG2a isotype control (MCA929PE)> Figure B. FITC conjugated Mouse anti Human CD86 (MCA1118F) and RPE conjugated Mouse anti Human HLA DP/DQ/DR (MCA477PE). All experiments performed on human Peripheral blood mononuclear cells in the presence of human SeroBlock (BUF070A).